Certified by Founder
Lodge
Kinaset Therapeutics
start up
- 13/01/2026
- Series B
- $103,000,000
At Kinaset Therapeutics, we intend to develop novel respiratory therapeutics that can positively impact people affected by intractable diseases. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma
- Industry Pharmaceutical Manufacturing
- Website https://www.kinasettherapeutics.com/
- LinkedIn https://www.linkedin.com/company/kinaset-tx/
WealthAi | $1,000,000 | (Jan 30, 2026)
Checkbox | $23,000,000 | (Jan 30, 2026)
PaleBlueDot AI | $150,000,000 | (Jan 30, 2026)
Mesh Security | $12,000,000 | (Jan 30, 2026)
Datalinx AI | $4,200,000 | (Jan 30, 2026)
Ressio Software | Undisclosed Amount | (Jan 30, 2026)
Co-reactive | $7,754,157 | (Jan 30, 2026)
Arkero | $6,000,000 | (Jan 30, 2026)
Redwood Materials | $425,000,000 | (Jan 30, 2026)
Twogee Biotech | $2,575,886 | (Jan 30, 2026)
Levellr | $2,500,000 | (Jan 30, 2026)
Indigo(1) | $50,000,000 | (Jan 30, 2026)
heyData | $16,500,000 | (Jan 30, 2026)